Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis

Nature Communications

Volumn 4, Issue , 2013, Pages

  Hosaka, Kayoko ^a   Yang, Yunlong ^a   Seki, Takahiro ^a   Nakamura, Masaki ^a   Andersson, Patrik ^a   Rouhi, Pegah ^a   Yang, Xiaojuan ^a   Jensen, Lasse ^a,d   Lim, Sharon ^a   Feng, Ninghan ^a   Xue, Yuan ^a   Li, Xuri ^b   Larsson, Ola ^a   Ohhashi, Toshio ^c   Cao, Yihai ^a,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SUN YAT SEN UNIVERSITY   (China)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IMATINIB; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; VERY LATE ACTIVATION ANTIGEN 1;

CANCER; DISEASE TREATMENT; DRUG; GENE EXPRESSION; NUMERICAL MODEL; TUMOR;

ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER INHIBITION; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN CELL; LUNG METASTASIS; METASTASIS; MICROVASCULATURE; NEOPLASM; PERICYTE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZAMIDES; CARCINOMA, LEWIS LUNG; CELL MOVEMENT; CELL PROLIFERATION; FIBROSARCOMA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHA1BETA1; LUNG NEOPLASMS; MICE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-SIS; PYRIMIDINES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880287596     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3129     Document Type: Article

References (44)

1. Bergsten, E. et al. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat. Cell Biol. 3, 512-516 (2001). (Pubitemid 32422089)
2. Li, X. et al. PDGF-C is a new protease-activated ligand for the PDGF alphareceptor. Nat. Cell Biol. 2, 302-309 (2000).
3. Pietras, K., Sjoblom, T., Rubin, K., Heldin, C. H. & Ostman, A. PDGF receptors as cancer drug targets. Cancer Cell 3, 439-443 (2003). (Pubitemid 38340290)
4. Westermark, B. & Heldin, C. H. Platelet-derived growth factor. Structure, function and implications in normal and malignant cell growth. Acta Oncol. 32, 101-105 (1993). (Pubitemid 23188521)
5. Xue, Y. et al. PDGF-BB modulates hematopoiesis and tumour angiogenesis by inducing erythropoietin production in stromal cells. Nat. Med 18, 100-110 (2012).
6. Zhang, J. et al. Differential roles of PDGFR-alpha and PDGFR-beta in angiogenesis and vessel stability. FASEB J. 23, 153-163 (2009).
7. Cao, Y., Cao, R. & Hedlund, E. M. Regulation of tumour angiogenesis and metastasis by FGF and PDGF signalling pathways. J. Mol. Med. 86, 785-789 (2008).
8. Nissen, L. J. et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumour neovascularization and metastasis. J. Clin. Invest. 117, 2766-2777 (2007). (Pubitemid 47529608)
9. Cao, R. et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat. Med. 9, 604-613 (2003). (Pubitemid 36597108)
10. Cao, Y. Direct role of PDGF-BB in lymphangiogenesis and lymphatic metastasis. Cell Cycle 4, 228-230 (2005). (Pubitemid 41365322)
11. Pietras, K., Pahler, J., Bergers, G. & Hanahan, D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 5, e19 (2008).
12. Cao, R. et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 6, 333-345 (2004). (Pubitemid 39361435)
13. Cao, Y. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Adv. Cancer Res. 100, 113-131 (2008). (Pubitemid 351932181)
14. Crawford, Y. et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumours refractory to anti-VEGF treatment. Cancer Cell 15, 21-34 (2009).
15. Cao, Y. Erythropoietin in cancer: a dilemma in risk therapy. Trends Endocrinol. Metab. 24, 190-199 (2013).
16. Lindahl, P. et al. Paracrine PDGF-B/PDGF-Rbeta signaling controls mesangial cell development in kidney glomeruli. Development 125, 3313-3322 (1998). (Pubitemid 28458331)
17. Lindahl, P., Johansson, B. R., Leveen, P. & Betsholtz, C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277, 242-245 (1997). (Pubitemid 27446080)
18. Cao, Y. Tumor angiogenesis and molecular targets for therapy. Front. Biosci. 14, 3962-3973 (2009).
19. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005). (Pubitemid 40093472)
20. McCarty, M. F. et al. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J. Clin. Invest. 117, 2114-2122 (2007). (Pubitemid 47219556)
21. Cao, R. et al. VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy. Proc. Natl Acad. Sci. USA 107, 856-861 (2010).
22. Hedlund, E. M., Hosaka, K., Zhong, Z., Cao, R. & Cao, Y. Malignant cellderived PlGF promotes normalization and remodelling of the tumor vasculature. Proc. Natl Acad. Sci. USA 106, 17505-17510 (2009).
23. Hynes, R. O. The extracellular matrix: not just pretty fibrils. Science 326, 1216-1219 (2009).
24. Martin, K. H., Slack, J. K., Boerner, S. A., Martin, C. C. & Parsons, J. T. Integrin connections map: to infinity and beyond. Science 296, 1652-1653 (2002). (Pubitemid 34579156)
25. Mancuso, M. R. et al. Rapid vascular regrowth in tumours after reversal of VEGF inhibition. J. Clin. Invest. 116, 2610-2621 (2006). (Pubitemid 44511625)
26. Schapira, K. et al. Genetic deletion or antibody blockade of alpha1beta1 integrin induces a stable plaque phenotype in ApoE-/-mice. Arterioscler. Thromb. Vasc. Biol. 25, 1917-1924 (2005). (Pubitemid 41243463)
27. Furuhashi, M. et al. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumours and an associated increase in tumor growth rate. Cancer. Res. 64, 2725-2733 (2004). (Pubitemid 38500608)
28. di Tomaso, E. et al. PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment. PLoS One 4, e5123 (2009).
29. Hedlund, E. M. et al. Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs. Proc. Natl Acad. Sci. USA 110, 654-659 (2013).
30. Cao, R. et al. Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc. Natl Acad. Sci. USA 109, 15894-15899 (2012).
31. Zhang, D. et al. Antiangiogenic agents significantly improve survival in tumorbearing mice by increasing tolerance to chemotherapy-induced toxicity. Proc. Natl Acad. Sci. USA 108, 4117-4122 (2011).
32. Xue, Y. et al. Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proc. Natl Acad. Sci. USA 105, 18513-18518 (2008).
33. Xue, Y. et al. Hypoxia-independent angiogenesis in adipose tissues during cold acclimation. Cell. Metab. 9, 99-109 (2009).
34. Lim, S. et al. Cold-induced activation of brown adipose tissue and adipose angiogenesis in mice. Nat. Protoc. 7, 606-615 (2012).
35. Cao, R. et al. Mouse corneal lymphangiogenesis model. Nat. Protoc. 6, 817-826 (2011).
36. Jensen, L. D., Cao, R. & Cao, Y. In vivo angiogenesis and lymphangiogenesis models. Curr. Mol. Med. 9, 982-991 (2009).
37. Xue, Y. et al. FOXC2 controls Ang-2 expression and modulates angiogenesis, vascular patterning, remodelling, and functions in adipose tissue. Proc. Natl Acad. Sci. USA 105, 10167-10172 (2008).
38. Religa, P. et al. Presence of bone marrow-derived circulating progenitor endothelial cells in the newly formed lymphatic vessels. Blood 106, 4184-4190 (2005). (Pubitemid 41775925)
39. Brakenhielm, E. et al. Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circ. Res. 94, 1579-1588 (2004). (Pubitemid 38856965)
40. Brakenhielm, E. et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc. Natl Acad. Sci. USA 101, 2476-2481 (2004). (Pubitemid 38269336)
41. Eriksson, A. et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 1, 99-108 (2002). (Pubitemid 41039180)
42. Dai, C., Whitesell, L., Rogers, A. B. & Lindquist, S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 130, 1005-1018 (2007). (Pubitemid 47410269)
43. Sandberg, R. & Larsson, O. Improved precision and accuracy for microarrays using updated probe set definitions. BMC Bioinformatics 8, 48 (2007).
44. Wright, G. W. & Simon, R. M. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 19, 2448-2455 (2003). (Pubitemid 38016644)